aceneuramic acid extended-release (Ace-ER)
UX001-CL301
Phase 3 small_molecule completed
Quick answer
aceneuramic acid extended-release (Ace-ER) for Hereditary Inclusion Body Myopathy is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Hereditary Inclusion Body Myopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed